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Abstract
The myelodysplastic syndromes (MDSs) are characterized by ineffective erythropoie‐
sis and progressive cytopenia and ultimately affected patients develop acute myeloid
leukemia (AML) or die from advanced bone marrow (BM) failure.
Myelodysplastic syndrome (MDS) with isolated del (5q) is a common type of MDS with
specific  pathological  and  clinical  manifestations  including  refractory  anemia.  It  is
usually treated by (1) supportive measures including blood transfusions that may cause
iron overload that requires iron chelation therapy, (2) targeted therapies such as the
immunomodulatory drug lenalidomide, and (3) hematopoietic stem cell transplanta‐
tion  (HSCT)  in  transplant  eligible  individuals.  The  establishment  of  the  various
prognostic systems, the discovery of the new genetic mutations, and the identification
of new targets, in MDSs in general and in 5q-syndrome in particular, will hopefully
translate  into  more  pinpointed  targeted  therapies  that  will  further  improve  the
outcomes of patients having these disorders.
Keywords: myelodysplastic syndrome, 5q-syndrome, iron overload, lenalidomide,
hematopoietic stem cell transplantation
1. Introduction
The MDSs are a group of clonal stem cell disorders that are characterized by ineffective
erythropoiesis due to excessive apoptosis and progressive peripheral blood cytopenia
culminating into acute myeloid leukemia AML or death from progressive BM failure [1–4].
MDS is primarily a disease of the elderly with a median age of 70 years [3]. The MDSs have
been linked to several etiologies, risk factors, and environmental associations such as alcohol
intake, tobacco use, Sweet’s syndrome, vitamin deficiencies, cytotoxic chemotherapy, various
hereditary disorders, and BM failure syndromes [5–12].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Pathogenesis of MDSs
The pathogenesis of MDS is poorly understood [5, 12]. However, several pathogenic mecha‐
nisms have been described and these include the following: (1) genetic mutations as the cell
of origin has acquired multiple mutations that result in dysplasia and ineffective erythropoi‐
esis; (2) MDS clonality: MDS is a clonal process thought to develop from a single-transformed
hematopoietic progenitor cell. The inciting mutation is unknown for the majority of cases.
However, recurrent genetic mutations involving RNA splicing machinery have been identi‐
fied; (3) haploinsufficiency of ribosomal proteins particularly ribosomal protein (RPS) 14 in
del (5q); (4) telomere dysfunction and aberrant or absent expression of micro-RNA species; (5)
epigenetic changes: MDS genomes are characterized by global DNA hypomethylation with
concomitant hypermethylation of gene-promoter regions relative to normal controls; (6)
factors extrinsic to hematopoietic cells such as stromal abnormalities and T-cell dysregulation
that may occur causally or secondary to the primary genetic defects; (7) accelerated apoptosis
and ineffective erythropoiesis; (8) altered immune responses such as polyclonal expansion of
helper T cells (CD4+) and oligoclonal expansion of cytotoxic T cells (CD8+) in the peripheral
blood and BM; (10) leukemic transformation in MDS; the estimated risk of leukemic transfor‐
mation is more than 50% and is more frequent in patients with high-risk MDS such as refractory
anemia with excess of blasts (RAEB) II, monosomy 7, deletion of short arm of chromosome 17,
deletion of long arm of chromosome 7, and trisomy 8 [5, 12].
3. Chromosome 5 abnormalities in MDS
Approximately, 15% of patients with MDS have abnormalities of chromosome 5 that include
insertional deletion of a segment of the long arm of the chromosome [del (5q) or 5q-syndrome],
monosomy 5, and unbalanced translocations [13].
3.1. Del (5q) type of MDS
The insertional deletion of the long arm of chromosome 5, del (5q), is the one of the most
common cytogenetic abnormality encountered in patients with MDSs as it has been reported
in 10–30% of patients with MDS [14–17]. The long arm of chromosome 5 has two distinct
commonly deleted regions (CDRs). The more distal CDR lies in 5q33.1 and contains 40 protein
coding genes and genes that code for microRNAs (miR-143 and miR-145) [13]. Many genes
related to hematopoiesis are located on the long arm of chromosome 5 [18]. In del (5q), one
allele is deleted and this accounts for the genetic haploinsufficiency [13]. The gene cluster at
5q31 includes interleukins (ILs) 3, 4, 5, 9, 13, and 17β in addition to granulocyte monocyte-
colony-stimulating factor (CSF). Several cytokine receptor genes are also located on the long
arm of chromosome 5 including: CSF-1 receptor and platelet-derived growth factor-β [18].
The world health organization (WHO) recognizes del (5q), which was first described by Van
den Berghe et al. in the year 1974, as a distinct form of MDS [15, 18–20]. The 5q-syndrome is
the most distinct type of all MDSs as it has clear genotype/phenotype relationship [18, 21]. If
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del (5q) occurs as the only cytogenetic abnormality, it is associated with favorable prognosis
but once it is encountered in association with other single or multiple chromosomal abnor‐
malities, particularly in the setting of complex cytogenetics, the clinical outcome is rendered
poor [14, 16, 20, 22, 23].
Patients with del (5q) have specific clinical and pathological features [15, 18, 20]. The 5 q-
syndrome is usually characterized by the following: (1) female predominance, (2) refractory
macrocytic anemia that is often severe, (3) normal or elevated platelet count, (4) BM findings
of erythroid hypoplasia, less than 5% blasts as well as abnormal, dysplastic or hypolobulated
megakaryocytes, (5) del (5q) chromosomal abnormality as the sole karyotypic abnormality,
and (6) a rather benign clinical course with approximately 10% of patients ultimately pro‐
gressing to AML [13, 14, 18–20].
Despite the remarkable progress that has been achieved recently, certain unclear issues related
to the pathogenesis of del (5q) need further evaluation [18, 20]. Del (5q) MDS is considered a
disorder of the hematopoietic stem cells with lympho-myeloid potential. Also, involvement
of B cells, rather than T cells, was documented by combining immunophenotyping and
fluorescence in situ hybridization (FISH) analysis [18]. Cytogenetic and FISH analysis in BM
progenitor cells have revealed that, in del (5q) MDS, the deletion was generally present in the
pluripotent hematopoietic stem cells (CD34+ and CD38+) with the persistence of the normal
progenitor cells in the BM [20]. Genomic stability in 5q-syndrome is related to the infrequency
of additional cytogenetic abnormalities [18]. The lack of mutations in the genes mapping the
CDR suggests that haploisufficiency is the basis of 5q-syndrome [13, 18, 20]. Candidate genes
that show haploinsufficiency in del (5q) include SPARC (secreted protein acidic and cysteine
rich), a tumor suppressor gene, and RPS14, which is a component of the 40s ribosomal subunit
[13]. Only in advanced forms of the disease, rare mutations involving p53, JAK2, and MPL
genes have been described [13, 18, 20].
The erythroid defect or failure in del (5q) appears to be multifactorial as it has been reported
to involve in the following: (1) the decreased expression or haploinsufficiency of the ribosomal
protein S14 [RPS14] gene, (2) the upregulation of the p53 pathway induced by ribosomal stress,
and (3) enhancement of the endogenous erythropoietin production that ultimately leads to red
cell transfusion dependence in most patients [13, 15, 18, 21]. On the other hand, loss of the
microRNA genes miR-145 and miR-146a has been associated with the thrombocytosis
observed in 5q-syndrome patients [21]. Also, the increased expression of Friend leukemia virus
integration 1(FLI1), which is one of the target genes of miR-145, maintains effective megakar‐
yopoiesis in del (5q) MDS resulting in normal or elevated platelet (PLT) counts [13].
Isolated del (5q) has been reported in in higher grade MDSs such as RAEB and RAEB-
thrombocytosis (RAEB-T), thus contributing to the heterogeneity of the disease [20, 22]. MDS
with del (5q) occurs not only in myelodysplastic disorders, but also in AML and it contributes
to the pathogenesis of both myeloid diseases by deleting one or more of the tumor suppressor
genes [22]. Once associated with additional cytogenetic abnormalities and once new genetic
mutations are acquired, such as TP53 mutation, MDS with del (5q) becomes an aggressive
disease with rapid evolution into AML [20, 22]. Therefore, isolated del (5q) MDS should be
differentiated from other forms of myelodysplasia having del (5q) associated with other
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cytogenetic abnormalities and an excess of BM blasts [20]. Other specific aspects of 5q-
syndrome will be discussed separately in the subsequent sections of the review manuscript.
3.2. Monosomy 5 type of MDS
Loss of the whole chromosome 5 has been described in about 3–8% MDS cases. Recent studies
have shown that many suspected monosomies 5 are in fact cryptic translocations or insertions,
undetectable by conventional G-banding [24]. The mechanism responsible for the fragmenta‐
tion of deleted chromosome 5 remains unclear. One of the possible explanations might be the
phenomenon called chromothripsis, whereby one or more chromosomes or chromosomal
regions shatter into pieces in a single catastrophic event. MDS patients with deleted chromo‐
some 5 involved in complex rearrangements should be considered as a unique entity with
extremely poor prognosis [24].
Monosomy 5 does exist but is rarely encountered and the presence of this chromosomal
abnormality is usually associated with complex karyotypes, conferring poor prognosis [25].
Studies have shown that, compared to 5q- syndrome, monosomy 5 is more frequently
associated with: advanced or higher risk MDS, other chromosomal abnormalities including
chromosome 7 abnormalities and inferior overall survival [26]. Monosomy 5 has been reported
in therapy-related MDS (t-MDS) with complex cytogenetics and rapid progression to death
[27].
4. Clinical manifestations and complications of MDS
MDS has nonspecific signs and symptoms at presentation. However, many patients are
asymptomatic at presentation. The main manifestations of MDS are those related to cytopenia.
Anemic manifestations include fatigue, weakness, dizziness, exercise intolerance, angina,
cognitive impairment, and altered sense of well-being [12, 28]. Patients having thrombocyto‐
penia present with bleeding from various sites such as skin and mucous membranes. Easy
bruising, epistaxis, petechiae, ecchymoses, and gum bleeding are the main manifestations [12,
28]. Patients with neutropenia may develop fever and infections may be due to viruses,
bacteria, fungi, and mycobacteria [12, 28, 29]. Physical examination in patients with MDS
usually reveals: pallor, petechiae or ecchymoses, hepatosplenomegaly, and lymphadenopathy
uncommonly, weight loss in advanced cases and skin manifestations in case of associated
Sweet’s syndrome [12, 28].
Autoimmune abnormalities may be present in MDS patients and they include cutaneous
vasculitis, monoarticular arthritis, pericarditis, pleural effusions, edema formation, skin
ulcerations, iritis, myositis, peripheral neuropathy, fever, and pulmonary infiltrates [12]. Other
abnormalities that may be encountered in patients with MDS include pure red cell aplasia,
acquired HbH disease, myeloid sarcomas, Sweet's syndrome, myocardial ischemia, and
thrombocytosis in patients with del (5q) and RARS-T [12, 28].
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5. Diagnosis and subtypes of MDS
Minimal morphological diagnostic criteria in MDS include the following: (1) BM findings: ≥
10% dysplastic cells in ≥ 1 myeloid lineages, (2) highly suggestive features: (a) granulocytic
series: agranular neutrophils and Pelger–Huet neutrophils, (b) megakaryocytes, small
binucleated megakaryocytes and small round separated nuclei in megakaryocytes, and (c)
erythroid series: multinuclear or asymmetrical nuclei, nuclear bridging, and ring sideroblasts
[6, 30, 31].
The minimal diagnostic criteria in MDS include the following: (1) prerequisite criteria that
include (a) constant cytopenia in ≥ 1 of the following lineages: erythroid: Hb < 11 g/dL,
neutrophilic; absolute neutrophil count (ANC) < 1.5 × 109/L or megakaryocytic, PLTs <
100 × 109/L. (b) exclusion of all other hematopoietic and nonhematopoietic disorders as primary
reasons for cytopenia or dysplasia; (2) MDS-related or decisive criteria: (a) dysplasia in at least
10% of all cells in one of the following lineages in the BM smear; erythroid, neutrophilic or
megakaryocytic or > 15% ring sideroblasts on iron staining, (b) 5–19% blasts on BM smears,
and (c) typical chromosomal abnormality by FISH or conventional karyotype. (3) cocriteria for
patients fulfilling (1) but not (2): (a) abnormal phenotype of BM cells clearly indicative of a
monoclonal population of erythroid and/ or myeloid cells determined by flow cytometry, (b)
clear molecular signs of a monoclonal cell population in human androgen receptor (HU‐
MARA) assay, gene chip profiling or point mutation analysis such as RAS mutation, (c)
markedly or persistently reduced colony formation of BM and/or circulating progenitor cells
by colony-forming unit assay [6, 30, 31]. The subtypes of MDS according to the WHO classi‐
fication are illustrated in Table 1 [6, 30, 31].
Subtype of MDS Proportion of MDS
patients
Peripheral blood
findings
Bone marrow findings
RAEB I
[refractory anemia with
excess of blasts I]
– Cytopenia (s)
<5% blasts
No Auer rods
Monocytes:
<1G/L or
<1 × 109/L
Unilineage or multilineage
dysplasia
No Auer rods
5–10% blasts
RAEB II
[refractory anemia with
excess of blasts II]
40% Cytopenia(s)
5–19% blasts
Possible Auer
rods Monocytes:
<1 G/L
or <1 × 109/L
Unilineage or multilineage
dysplasia
5–19% blasts
Possible Auer rods
RCUD
[refractory anemia with
unilineage dysplasia, uni
Refractory:
Anemia: 10–20%
Neutropenia: < 1%
Anemia
Neutropenia
Thrombocytopenia
Only one cytopenia with
dysplasia in >10% of cells.
> 5% blasts< 15% ring
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Subtype of MDS Proportion of MDS
patients
Peripheral blood
findings
Bone marrow findings
or bicytopenia] ↓ PLT: < 1% No or < 1% blasts sideroblasts
RARS
[refractory anemia ring
sideroblasts]
3–11% Anemia
No blasts
Unilineage erythroid
dysplasia
< 5% blasts
≥ 15% ring siderblasts
RCMD
[refractory anemia with multi
lineage dysplasia with or
without ring sideroblasts]
30% Cytopenia(s)
< 1% blasts
No Auer rods
Monocytes
< 1 G/L
Dysplasia in ≥ 10% of cells
belonging to at
least 2 cell lines
< 5% blasts without
Auer rods
± 15% ring sideroblasts
MDS with isolated del (5q) Uncommon Anemia
Normal or
high PLT
count
< 1% blasts
5% blasts without Auer rods
Megakaryocytes: normal or ↑;
hypolobulated
MDS-U
[unclassified MDS]
Unknown
percentage
Cytopenia
≤ 1% blasts
Dysplasia in < 10% cells
but cytogenetic
abnormalities are considered
presumptive for
MDS
< 5% blasts
MDS: myelodysplastic syndrome; PLT: platelet; ↑: increased.
Table 1. WHO classification of MDS.
5.1. Cytogenetics in MDS
Several cytogenetic abnormalities can be encountered in patients with MDSs, some of these
are balanced, while others are unbalanced as illustrated in Table 2 [6]. Cytogenetic abnormal‐
ities are major determinants in the pathogenesis of MDS. They are becoming increasingly
recognized as the basis of selecting drugs in individual patients with MDS and they play a
significant role in monitoring response to treatment [32]. Chromosomal abnormalities are
detected in approximately 50% of patients with de novo MDS and 80% of patients with t-MDS
[32]. Recently, our ability to define the prognosis of the individual patient with MDS has
improved significantly [6]. Cytogenetic abnormalities are becoming essential in determining
the prognosis of MDS because they constitute the basis of the new cytogenetic scoring system
as shown in Table 3 [31, 33, 34]. The values of the new prognostic systems will certainly become
higher as new genetic-based therapy move through trials and into clinical practice [6].
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Balanced chromosomal abnormalities Unbalanced chromosomal abnormalities
Abnormality Frequency Abnormality Frequency
t (11,16) (q23;p13.3) – +8 10%
t (3,21) (q26. 2; q22.1) – −7 or del (7q) 10%
t (1,3) (p36.3; q21.2) – −5 or del (5q) 5–8%
t(2,11) (p21; q23) 1% Del (20q) 5%
inv (3) (q21; q26.2) 1% −Y 3–5%
t (6,9) (p23; q34) 1% I (17q) or t (17p) 3%
−13 or del (13q) 3%
Del (11q) 10%
Del (12p) or t (12p) 3%
Del (9q) 1–2%
Idic (x) (q13) 1–2%
*MDS: myelodysplastic syndrome.
Table 2. Chromosomal abnormalities in MDS.
Prognostic
class
Proportion of
patients
Karyotype or cytogenetic
abnormalities
Median survival
in years
Time to 25% AML
transformation
Very good 4% −Y
del (11q)
5.4 Not reached
Good 72% Normal
del (5q)
del (20q)
del (12q)
Double including del (5q)
4.8 9.4
Intermediate13% del (72)
+8
+19
isochromosome (17q)
Any other single or double
independent clones
2.7 2.5
Poor 4% −7
inv (3); t(3q); del (3q)
Double including -7/del (7q)
Complex: 3 cytogenetic abnormalities
1.5 1.7
Very poor 4% Complex > 3 cytogenetic abnormalities0.7 0.7
MDS: myelodysplastic syndrome; AML: acute myeloid leukemia.
Table 3. New cytogenetic scoring system for MDS.
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5.2. Impact of monosomal karyotype on the prognosis of MDS
A monosomal karyotype (MK) is defined by the presence of ≥ 2 distinct autosomal chromosome
monosomies or a single autosomal monosomy associated with ≥ 1 structural abnormality [1].
In AML, MK has been associated with a worse prognosis than an otherwise complex karyo‐
type, regardless the specific type of autosome involved [1].
Studies have shown that MK in MDS identifies a prognostically worse subgroup of patients
than a complex karyotype regardless of whether monosomy 7 or 5 is part of the MK component
[1]. Chromosomal abnormalities are present in 20–70% of patients with MDS, but complex
cytogenetics are universally considered unfavorable as they are associated with poor overall
survival (OS) and high rates of leukemic transformation [1, 32, 34].
5.3. Genetic mutations described in MDSs and 5q-syndrome
Several classes of genetic mutations have been described in patients with MDS as shown in
Tables 4–6 [34–40]. These mutations are essential in not only determining the prognosis but
also constituting a platform for the current and future novel and targeted therapies for various
types of myelodysplasia (Tables 4 and 6) [34–39].
Class Mutation Chromosomal
location
Frequency Prognostic
significance
– Associations:
phenotypes
and MDS types
– Application to
treatment
(1) RNA- splicing
machinery
(50%)
SF3B1
[Splicing factor 3b,
subunit 1]
2q33.1 15–60% Good – Phenotype: ring
sideroblasts
– MDS types: – RARS
– RCMD – RS
– RARS – T
SRSF2
[Serine/arginine-rich
splicing factor-2]
17q22.3 6–20% Poor – MDS types:
– RCMD
– RAEB
– CMML
U2AF1
[U2 small nuclear RNA
auxiliary factor-1]
21q22.3 5–12% Unclear/poor – MDS types:
– RCMD
– RAEB
– CMML
ZRSR2
[Zinc finger RNA-
binding mofit and
serine/arginine rich 2]
Xp22.1 3–10% Unknown – MDS types:
– RCMD
– RAEB
– CMML
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Class Mutation Chromosomal
location
Frequency Prognostic
significance
– Associations:
phenotypes
and MDS types
– Application to
treatment
ZRSF2 17q25.1 6–12% Poor –
PRPF8 17p13.3 3.3% Unclear –
(2)
Epigenetic
pathways:
DNA methylation
and chromatin
modification
(45%)
DNMT3A
[DNA methyltransferase
3 alpha]
2 p23 8–12% Adverse/
negative
– Decreased
survival
– Increased risk
of sAML
– All MDS types
TET 2
[tetmethylcytosine
deoxygenase-2]
4q 24 15–30%
2%
Unclear /
possibly
positive
– Improved
response to
azacitidine
– Inconsistent
impact on
survival
– Phenotype: myeloid
dominancy
– MDS types:
dominancy
– all MDS types
– Normal karyotype
– CMML
IDH1
[isocitrate
dehydrogenase-1]
(soluble)
2q 33.3 2% Unclear
– Advanced
MDS
– AML
progression
– MDS types:
– RCMD
– RAEB
– CMML
IDH2
[isocitrate
dehydrogenase-2]
(mitochondrial)
15q 26.1 2% Poor prognosis
– Decreased
survival
– MDS types:
– RCMD
– RAEB
– CMML
EZH2
[enhancer of
zeste homolog 2]
−7/7q-
7q35–q36
2–6% Poor prognosis
– Decreased
survival
– MDS types:
– RCMD
– RAEB
– CMML
ASXL1
[additional sex
combs like 1]
20q 11 10–21% Poor prognosis
– Decreased
survival
– MDS types:
– RCMD
– RAEB
– CMML
(3) Signal
transduction
NRAS
[neuroblastoma
1 p13.2 10% Unclear/
adverse
– MDS types:
– All MDS types
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Class Mutation Chromosomal
location
Frequency Prognostic
significance
– Associations:
phenotypes
and MDS types
– Application to
treatment
(kinase signaling) RAS viral oncogene
homolog]
– Increased
risk of
progression
to AML
– CMML
– JMML
KRAS 12 p12.1 2–6% Unclear/
adverse
– Increased
risk of
progression
to AML
– MDS types:
– All MDS types
– CMML
– JMML
CBL
[cbl proto-
oncogene E3 ubiquitin
protein ligase]
11q 23.3 1–5% Unknown – MDS types:
– All MDS types
– CMML
– JMML
JAK 2
[Janus kinase 2]
9p24 6.2–8.3% Unknown
– Does not
appear to alter
prognosis
– Phenotype:
– Megakaryocytosis
– MDS types:
– all types/RARS-T/RA
– JAK2 Inhibitors
NF1 – <5% Poor – MDS types:
– all MDS types
– JMML
FLT3
[Fms-related
tyrosine -kinase 3]
13 q12 <5% – Poor
prognosis
– Progression
to AML
– MDS types:
– All MDS types
– FLT 3 Inhibitors
(4)
Cohesin family-
complex pathway
RAD 21 8 p24 2% – Adverse
prognosis
–
STAG 2 X q25 5–10% – Adverse
prognosis
– MDS types:
– RCMD
– CMML
– RAEB
SMC1 A Xp 11.22-
P11.121
<1% – Adverse
prognosis
–
SMC 3 10q25 2% – Adverse
prognosis
–
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Class Mutation Chromosomal
location
Frequency Prognostic
significance
– Associations:
phenotypes
and MDS types
– Application to
treatment
(5)
Transcriptional
factors and
corepressors
TP 53
[tumor protein
P53]
17q13.1 5–10% – Very poor
– Adverse
outcome
– Phenotype:
– Complex karyotype
– Poor prognosis
– Rapid progression to
AML
– MDS types:
– RAEB
– Isolated del (5q)
– Therapy related MDS
RUNX1
[runt-related
transcription
factor 1]
21q22.3 9–20% – Adverse
outcome
– Very poor
– Associated
with -7/del (7q)
– *High risk of
progression to
AML
– Phenotype:
thrombocytopenia
– MDS types:
– RCMD
– RAEB
– CMML
BCOR1/BCORL1 Xp 11.4/X q25-
q26.1
6–9.1% – Adverse
outcome
– MDS types:
– RCMD
– RAEB
CEBPA
[CCAAT/enhancer-
binding protein, alpha]
19q13.1 <5% – Poor
prognosis
– MDS types:
– RCMD
– RAEB
ETV6
Ets variant-6
12 p13 <5% – Poor outcome – MDS types:
– RCMD
– RAEB
SETBP1
SET-binding protein1
18q21.1 2–5% – Negative/
adverse
outcome
–
KMT2A
Lysine -K-specific
methyltransferase-2A
11q21.1 Approximately
4%
– Negative/
adverse
outcome
–
NPM1
nucleophosmin
5q35.1 Approximately
2%
Unknown –
KIT 4q11-q12 Approximately
1%
Unclear –
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Class Mutation Chromosomal
location
Frequency Prognostic
significance
– Associations:
phenotypes
and MDS types
– Application to
treatment
[V-KitHardy-Zuckerman
4 Feline sarcoma viral
oncogene homolog]
(6) Other genetic
mutations
GNAS
[GNAS complex 10ms]
20q 13.3 Approximately
1%
Unknown
PTPN11
Protein tyrosine
phosphatase non-
receptor type11
12q 24 Approximately
1%
Unknown
PTEN 10q 23 <1% –
CDKN2A 9q (12) <1% –
BRAF 7q 34 <1% –
CSF1R – – – Poor
prognosis
– Advanced
MDS
– Progression to
AML
– Normal karyotype
predominantly
ATRX – Rare Associated with
acquired α-thalassemia,
often with severe
anemia
MPL – – – Poor
prognosis
– Advanced
MDS
– Progression to
AML
5% of RARS – T
MDS: myelodysplastic syndrome; CMML: chronic myelomonocytic leukemia; JMML: juvenile myelomonocytic
leukemia; AML: acute myeloid leukemia; RCMD: refractory cytopenia with multilineage dysplasia; RA: refractory
anemia; RAEB: refractory anemia with excess of blasts; RARS: refractory anemia with ring sideroblasts; RARS-T:
refractory anemia with ring sideroblasts thrombocytosis.
Table 4. Genetic mutations in MDS.
TP53 encodes a cytoplasmic protein p53 that regulates cell growth and death. TP53 mutations
have been found mainly in intermediate to high-risk MDS patients [41]. Patients having TP53
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mutations often present with severe thrombocytopenia, complex cytogenetic abnormalities,
an increased risk of leukemic transformation, and a shorter survival [41, 42]. Patients with
mutant p53, compared to patients carrying wild-type p53, have the following features: older
age, anemia, and leucopenia at the time of diagnosis and shorter median survival. Molecular
identification of mutant p53 contributes to the risk stratification of patients with lower-risk
MDS that may alter the treatment approach [41]. TP53 mutations develop at an early disease
stage in almost 20% of patients with lower-risk MDS having del (5q) [42].
Biological process Genetic mutation
Transcriptional regulators – SF3 B1 nm – SRSF2 nm
– UZ AF1 – CUX1
– SETBP1
Epigenetic regulators – ASXL1 – TET2 nm
– DNMT3 A – EZH2
Cell cycle regulators – TP53
– NPM1
Apoptosis – BCL2
Translation – RPS14 nm –RPL 23
– RPS 4x – RPS 25
– RPA 19
Signaling or differentiation – RUNX1 – N-RAS
– ETV 6 – FMS
– FLT 3 – SET BP1
*MDS: myelodysplastic syndrome;
* nm: non-mutated
Table 5. Genetic mutations associated with poor prognosis in MDS.
Mouse models of the 5q-syndrome have indicated that a p53-dependent mechanism underlies
the pathophysiology of this disorder. Importantly, activation of p53 has been demonstrated in
the human 5q-syndrome [43]. Recurrent TP53 mutations have been associated with an
increased risk of AML disease evolution and with decreased response to lenalidomide therapy
in del (5q) MDS patients [43].
TP53 mutations are usually present years before disease progression. They are associated with
p53 overexpression but are not associated with specific clinical manifestations [42]. The
presence of TP53 mutations in low-risk MDS with del (5q) contributes to the heterogeneous
disease and may significantly affect clinical decision making [42].
Myelodysplastic Disorders, 5q-Syndrome
http://dx.doi.org/10.5772/64202
107
Pathway Examples of
genetic mutations
Frequency in MDS
(%)
Application to treatment
DNA splicing machinery – SF3B1, – UZAF1
– SRSF1, – PRPF8
– SRSR2/SRSF2, – UTx
60–70% None
DNA methylation – DNMT3A
– TET2
– IDH1/IDH2
40–50% – DNA methyl transferase inhibitors
– IDH1/IDH2 inhibitors
Chromatin modification – ASXL1
– EZH2
20–30% – Deacetylyase inhibitors
Signal transduction – NRAS/KRAS
– CBL
– JAK2
– NF1
– FLT3
20–30% – Kinase inhibitors
– JAK inhibitors
– FLT3 inhibitors
Cohesion complex/family
pathway
– STAG2
– RAD21
– SMC1A
– SMC3
10% None
Transcription factors and
corepressors
– TP53
– RUNX1
– BCOR1/BCORL1
– CEBPA
– ETV6
20–40% None
MDS: myelodysplastic syndrome.
Table 6. Point mutations in MDS.
In patients with 5q-syndrome, TP53 mutations are present in a small fraction of patients and
they cause p53 overexpression subsequently. These aberrant subclones remain quiescent
during treatment with lenalidomide and they expand at transformation into acute leukemia
[44]. Studies have confirmed that in patient with low-risk MDS having 5q-syndrome, TP53
mutations are associated with strong p53 expression and that p53 positivity is the strongest
independent predictor of transformation into AML [45]. Patients with MDS having del (5q)
may have mutations other than TP53 such as FOXP1, TP63, JAK2, and MPL mutations [19,
46]. FOXP1 and TP63 mutations may be involved not only in the pathogenesis of the disease,
but also they may play a role in the progression into AML [46]. JAK2 and MPL mutations may
be found in a small proportion of patients, but their presence does not seem to affect phenotype
or progression [19].
Potential new therapeutic agents for del (5q) MDS include the translation enhancer L-leucine,
as it may have some efficacy in ribosomopathies. L-leucine has shown increased hemoglobi‐
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nization and red cell numbers and reduced developmental defects both in humans and in
mouse models [43].
6. Prognostic systems in MDSs
In MDS, there are several prognostic scoring systems and these include the following: (1) the
international prognostic scoring index (IPSS), (2) the revised IPSS (R-IPSS) (Table 7), (3) the
WHO prognostic scoring system (WPSS), (4) MD Anderson Cancer Center (MDACC) MDS
model that includes the global and the lower-risk scoring systems, and (5) the French prog‐
nostic scoring system (FPSS) [30, 31, 33, 47, 48]. The components of the prognostic stratification
systems of MDS are as follows: BM blast cells, age, comorbid medical conditions, serum lactic
dehydrogenase (LDH), cytogenetics, number of cytopenia, severity of anemia, and high white
blood cell (WBC) count [4].
Prognostic variable Points
0 0.5 1 1.5 2 3 4
Cytogenetics Very good – Good – Intermediate Poor Very poor
Bone marrow blasts % ≤2 – >2–5% – 5–10% >10% –
Hb (g/dL) ≥10 – 8– < 10 <8 – – –
PLT count
×109/L
≥100 50–100 <50 – – – –
ANC
×109/L
≥0.8 <0.8 – – – – –
MDS: myelodysplastic syndrome; Hb: hemoglobin; ANC: absolute neutrophil count – indicates not applicable; PLT:
platelet.
Table 7. (R-IPSS) Revised international prognostic scoring system for MDS.
The IPSS is composed of: blast percentage, karyotype or cytogenetics and the number of
cytopenia. The IPSS is classified into low, intemediate-1, intemediate-2, and high-risk score [6,
49]. The R-IPSS model incorporates: BM blasts, cytogenetics, hemoglobin (Hb) level, PLTs, and
ANC. The R-IPSS is divided into five risk categories: very low, low, intermediate, high, and
very high risks (Table 7) [30, 31, 33, 47]. The R-IPSS is an excellent predictor of MDS in the era
of disease modifying therapies. The early recognition of patients at high risk of progression to
aggressive disease may optimize the timing of treatment before worsening of comorbidities
[50]. The precise definition of a prognostic score, such as the R-IPSS, and the probability of
leukemia evolution are particularly important in patients with lower-risk MDS in which new
approaches including allogeneic HSCT may be addressed in younger patients in a refined
manner [50].
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The WPSS incorporates the following variables: WHO classification of MDS, cytogenetics, and
the need for RBC transfusions [6, 47]. The MD Anderson prognostic model depends on the
following factors: age, performance status, prior blood transfusion, WBC and PLT counts, Hb
level, BM blasts, and karyotype [47, 49]. The scoring system is divided into four risk categories:
low, intermediate-1, intermediate-2, and high [47, 49]. The FPSS includes the following items:
the Eastern Cooperative Oncology Group (ECOG) performance status, IPSS cytogenetic risk,
the presence of circulating blasts, and packed red blood cell (RBC) transfusion dependency
[48]. The prognostic models of MDS are important, as they are used as tools in determining
the severity of the illness, the prognosis of MDS, and the best line of management to be
considered, that is, supportive care, hypomethylating agents, immunomodulatory drugs or
HSCT [49]. The proliferation index (PI) of specific compartments of BM cells is a dynamic
parameter that reflects the ongoing rate of production of hematopoietic cells in MDS. It is
directly related to the maturation-associated alteration of distinct subgroups of hematopoietic
cells in individual patients [4]. Assessment of the PI of nucleated RBCS and other components
of BM precursors, such as myeloid CD34+ hematopoietic progenitor cells, could significantly
contribute to a better management of MDS. The PI of nucleated RBCS is emerging as an
independent prognostic factor for both OS and progression-free survival (PFS) in MDS [4].
7. Anemia and iron overload in MDSs and 5q-syndrome
Anemia is a very common finding in MDS patients [51, 52]. Packed RBC transfusions are the
only therapeutic option in 40% of MDS patients [51, 52]. RBC transfusions are considered in
MDS patients when Hb level falls below 8 g/dL and may provide temporary relief of anemic
symptoms [51, 52]. Anemia contributes to cardiac dysfunction predominantly in elderly
individuals [51]. In MDS patients, anemia can be corrected by the following: (1) RBC transfu‐
sions, (2) administration of hematopoietic growth factors such as erythropoietin, (3) adminis‐
tration of certain drugs such as lenalidomide, cyclosporine-A, and antithymocyte globulin
(ATG), and (4) allogeneic HSCT that is the only curative therapeutic approach [51, 52].
Anemia and blood transfusions have significant impact on the quality of life (QOL) of MDS
patients [51]. Transfusion dependency is associated with shortened overall and leukemia-free
survival in MDS patients [51]. In these patients, transfusion dependency and iron overload
have been retrospectively associated with: (1) inferior survival, (2) worse clinical outcome
including cardiac, hepatic, and endocrine dysfunction and in some studies, (3) leukemic
transformation, and infectious complications [52].
The most serious side effects of regular blood transfusion are elevation of iron blood levels
and iron overload, that is, deposition of iron in body tissues [51–54]. Magnetic resonance
imaging (MRI) of the heart and liver is an excellent noninvasive diagnostic tool for (1) the
assessment of iron overload and (2) monitoring the response to iron chelation therapy [51, 55,
56]. MRI of the heart and liver is superior to the surrogate markers of iron overload such as
serum ferritin, liver iron, ventricular ejection fraction, and tissue-related parameter [51]. The
diagnostic parameters used for the evaluation of iron overload in MDS are shown in Table 8
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[55]. Serum erythropoietin is a predictive factor for response to therapy with subcutaneous
erythropoietin [57]. MDS patients with higher values of erythropoietin have poorer response
to the administration of erythropoietin therapy even at higher doses [57].
Method Normal level Mild to moderate iron overload Severe iron overload
Serum ferritin (ng/mL) <400 1000–2500 >2500
Transferrin saturation
(%)
20–40 50–70 >70
Labile plasma iron
(MM)
<0.4 >0.4 >0.4
Liver T2-MRI
(ms)
<6.3 <6.3 <1.4
Cardiac T2-MRI
(ms)
>20 8–20 <8
* MDS: myelodysplastic syndrome. * MRI: magnetic resonance imaging.
Table 8. Diagnostic parameters used for evaluation of iron overload in MDS.
7.1. Iron overload in low-risk MDS
In patients with low-risk MDS, packed RBC transfusion are required to correct anemia.
Ultimately, these patients become transfusion dependent [55, 58, 59]. Also, more aggressive
disease is usually associated with a high transfusion rate and thus significant transfusion
dependency becomes a surrogate marker of aggressive disease [59]. On the long-term,
transfusion dependence leads to the development of iron overload, which becomes an
important clinical problem, that is associated with an increase in morbidity and mortality [59].
However, in some transfusion-independent low-risk MDS patients, an increased erythro‐
poietic activity results in the suppression of hepcidin and contributes to iron loading [55].
In patients with low-risk MDS who are chronically transfused, transfusion-related morbidity
is an emerging challenge [58]. Blood transfusion therapy may lead to organ toxicity due to the
formation of nontransferrin bound iron and resulting in oxidative stress. Therefore, in low-
risk MDS patients with longer life expectancy, preventing organ damage due to iron overload
is an important concern [59].
Recently, high serum ferritin level has been identified as a prognostic factor for short time to
progression to acute leukemia [59]. Transfusion-dependent patients with an isolated erythroid
dysplasia and a low risk of leukemic transformation are more likely to develop parenchymal
iron overload and its toxicity and hence benefit from iron chelation therapy [56]. In low-risk
MDS patients with relatively lower RBC transfusion requirements, T2-MRI is indicated every
10–20 units of packed RBCS in order to evaluate the need to: (1) initiate iron chelation therapy,
(2) assess the effectiveness of treatment, and (3) determine the need for dose adjustment [55].
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Currently, the initiation of iron chelation therapy is based on: (1) the total number of RBC
transfusions and (2) increased serum ferritin in transfusion-dependent patients [55]. Iron
chelation therapy is generally recommended for selected patients with low-risk MDS [52–54].
It is reasonable to offer iron chelation therapy to low-risk MDS patients who are at high risk
of developing iron overload [55, 59]. Data from multiple retrospective studies have demon‐
strated that iron chelation therapy results in marked survival benefit in patients with low-risk
MDS [52, 55].
8. Management of MDSs and 5q-syndrome
Most patients with MDS are treated with supportive measures due to their old age and
comorbid medical conditions [3]. However, there are various therapeutic options for patients
with low or intermediate-1 risk MDS and these include the following: (1) blood product
transfusions: packed RBCS and PLTs, (2) iron chelation therapy with: deferasirox, deferoxa‐
mine, and deferiprone, (3) erythropoietin with or without granulocyte-CSF, (4) ATG and
cyclosporine-A, (5) danazol, (6) pyridoxine, (7) valproic acid, (8) lenalidomide, (9) 5-azaciti‐
dine, (10) decitabine, and (11) low-dose cytarabine [60].
8.1. Iron chelation therapy
The role of iron chelation therapy in MDS patients with transfusion dependency and iron
overload remains a very controversial issue in the management of MDS, mainly due to lack of
solid prospective clinical trials [52, 59, 61]. However, case–control studies, retrospective
analyses, and phase-II clinical trials have indicated that iron chelation therapy reduces iron
overload as measured by serum ferritin and may even prolong overall survival [54].
Iron chelation therapy is indicated in the following categories of patients: (1) patients with
frank iron overload; stable or increasing serum ferritin > 1000 ng/mL without signs of active
inflammation or liver disease; who are transfusion-dependent at any frequency and have a life
expectancy of >1 year, (2) transfusion-dependent patient who receive > 2 units of packed RBCs
per month, at any serum ferritin level, and have a life expectancy of > 2 years, except for patients
with frank iron deficiency such as chronic gastrointestinal (GIT) bleeding, and (3) in selected
patients, iron chelation therapy is considered when life expectancy < 2 years. Examples include:
planned curative treatment such as HSCT, massive iron overload with consecutive organ
dysfunction or massive iron overload that is judged to significantly reduce QOL [51, 58].
Additional parameters that may influence decision to treat with iron-chelating agents in
selected MDS patients include the following: (1) old age, (2) social and mental circumstances,
(3) comorbidity and organ dysfunction, and (4) genetic status such as HFE gene mutations [51,
58]. The guidelines of the National Comprehensive Cancer Network (NCCN) and those of the
MDS Foundation for the treatment of iron overload in MDS are illustrated in Table 9 [52, 55].
The proposed response criteria for iron chelation therapy in MDS are shown in Table 10 [58].
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Source Transfusion status Serum ferritin
level
ng/mL or mg/L
MDS risk category Patient profile
NCCN – Received >20 RBC units >2500 Mg/L IPSS: low or intermediate Candidate for allogeneic
HSCT
MDS
foundation
– Continuing transfusion >1000 mg/L – IPSS: low or intermediate
– WHO: RA/RARS/5q-
– Candidate for allogeneic
HSCT – No erythroid response
to primary therapy
MDS: myelodysplastic syndrome; HSCT: hematopoietic stem cell transplantation; IPSS: international prognostic
scoring index; WHO: world health organization; RA: refractory anemia; RARS: refractory anemia with ring
sideroblasts.
Table 9. Guidelines for the treatment of iron overload in MDS.
Complete response (CR) Minor response (MR) Stable iron load No response
Decrease in serum ferritin to
<200 ng/mL or Decrease in
serum ferritin by 500 ng/mL
Decrease in serum ferritin to <
200 ng/mL or Decrease in serum
ferritin by less than 500 ng/mL
Constantly elevated
serum ferritin but
<4000 ng/mL
Further increase in
serum ferritin by at
least 500 ng/mL or serum
ferritin level constantly
above 400 ng/mL
MDS: myelodysplastic syndrome.
Table 10. Proposed response criteria for iron chelation therapy in MDS.
There are three forms of iron-chelating agents, namely (1) oral deferasirox (exjade), (2) oral
deferiprone (feriprox), and (3) parenteral deferoxamine (desferal) [54, 58]. The availability of
two effective oral chelating agents, deferasirox and deferiprone, has renewed interest in the
evaluation of iron chelation therapy in MDS [52].
The beneficial effects of iron chelation therapy in MDS patients having iron overload include
significant reduction of: labile plasma iron, nontransferrin-bound iron and reactive oxygen
species (ROS) that mediate tissue damage observed in iron overload [52]. Adverse effects of
iron chelation therapy include cost and toxicity. Therefore, MDS patients should be initiated
on iron chelation therapy after weighing potential risks and benefits for each patient until more
definitive data are available [53]. Application of recent advances in the treatment of MDS can
reduce or eliminate the need for blood product transfusions thus minimizing the risk of iron
overload [54]. Careful attention to iron parameters with early initiation of iron chelation
therapy in patients with evidence of transfusion-related iron overload is an important
component of high-quality MDS care [61].
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8.2. Lenalidomide
There are 40 genes in the CDR on the long arm of chromosome 5 in MDS with del (5q). Examples
of the CDR genes and the effects of lenalidomide on the haplodeficient genes are shown in
Table 11 [13, 62, 63].
Gene Effect of deletion phenotype Effect of
lenalidomide
Functional effect
of lenalidomide
SPARC Increased cell adhesion – Anemia
– Thrombocytopenia
Increased expression
in MDS CD34+ cells
ex vivo
– Inhibition of
proliferation and
adhesion
RPS 14 Defective ribosomal
processing
– Macrocytic anemia Increased expression
in patients with
del (5q)
Erythroid response
EGR1 Decrease in tumor
suppressors
– Leukocytosis
– Anemia
– Thrombocytopenia
Increased expression
in an MDS-related
del (5q) cell line
Reduced proliferation
miR145
miR-146a
Elevated innate
immune signaling
– Thrombocytosis
– Neutropenia
– Megakaryocytic
dysplasia
Increased expression
in patients with
del (5q)
Possible anti-inflammatory
CDC 25C1
PP2A
Defective G2 – M
phase regulation
G1 and G2 M arrest
and apoptosis
– Direct inhibition of:
CDC 25 C – Indirect
inhibition of: PP2 A
G1 and G2 M arrest and
apoptosis Restoration of
erythropoiesis
DIAPH Defective cytoskeleton
tumor suppression
Clonal dominance Unknown; to be
determined
Unknown
Immunomodulatory
Antiproliferative
MDS: myelodysplastic syndrome.
Table 11. Genes in the commonly deleted region and effects of lenalidomide on the haplodeficient genes.
Lenalidomide is a novel thalidomide analog that has enhanced immunomodulatory and
antiangiogenic effects and diminished thalidomide-related adverse events [60]. The approved
indications of lenalidomide treatment in MDS include the following: (1) patients with del (5q)
who have symptomatic transfusion-dependent anemia, (2) lower risk, according to IPSS, MDS
patients having 5q- syndrome, and (3) other low-risk and intermediate 1 risk types of MDSs
[60, 62].
The important clinical trials of lenalidomide in patients with MDS are shown in Table 12 [60,
62–66]. Lenalidomide has several mechanisms of action that include the following: (1)
promotion of erythropoiesis by inhibition of CD45 protein tyrosine phosphatase and activation
of EPO-R/STAT5-signaling pathway, (2) the stimulation of production of certain ILs such as
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IL-2, IL-10, and interferon (IFN) -δ, (3) inhibition of pro-inflammatory cytokines and chemo‐
kines such as tumor necrosis factor (TNF)-α, IL-12, IL-1B, IL-6, monocyte chemotactic pro‐
tein-1, and macrophage anti-inflammatory protein-1α, (4) anti-angiogenic effects of
lenalidomide-mediated through endothelial cell migration inhibition, that is, inhibition of
bFGF-, VEGF-, and TNF-α-induced endothelial cell migration, (5) immunomodulatory effects,
(6) anti-inflammatory properties, (7) direct antineoplastic activity by the inhibition of malig‐
nant clone and upregulation of SPARC gene, (8) direct cytotoxic effect on abnormal del (5q)
clones by targeting haploinsufficient genes and their pathways, (9) T-cell activation or
stimulation of T-cell proliferation including natural killer (NK) cells number and function and
production of multiple cytokines, and (10) inhibition of haplodeficient phosphatases and
release of progenitors from p53 arrest [14, 21, 60, 62, 63, 67]. The adverse effects of lenalidomide
include the following: (1) myelosuppression: neutropenia, anemia and thrombocytopenia, (2)
venous thromboembolism such as deep venous thrombosis in 3.4% of treated patients, (3)
infectious complications such as pneumonia, fever and febrile neutropenia, (4) skin rashes,
pruritis, and urticaria, (5) GIT upset including nausea and diarrhea, (6) fatigue, muscle cramps,
and bone pains, (7) bleeding diathesis, (8) hypokalemia, (9) autoimmune hemolytic anemia,
(10) edema formation, and (11) rarely, hypothyroidism and hypogonadism [15, 17, 60, 62, 64,
68]. The mechanisms of resistance to lenalidomide include the following: (1) over expression
of PP2A and (2) restoration of p53 expression leading to accumulation of p53 [62].
Cereblon, an E3 ligase protein, was first described to be the molecular target of lenalidomide
in a seminal paper, published in the year 2010, that linked its role to the teratogenic effects of
thalidomide in zebrafish and chicks [69, 70]. In 2011, cereblon was found to play a key role in
mediating the antiproliferative and immunomodulatory activities of lenalidomide and
pomalidomide in multiple myeloma (MM) and T cells, respectively [69, 70]. Thalidomide has
been shown to bind and inhibit cereblon and cereblon loss had been found to cause birth defects
[71]. Studies on MM cell lines have shown lack of correlation between cereblon expression and
sensitivity to lenalidomide. However, in MM cell lines, made resistant to lenalidomide and
pomalidomide, cereblon protein was greatly reduced [69–71].
The central role of cereblon as a target of lenalidomide and pomalidomide suggests its potential
utility as a predictive biomarker of response or resistance to immunomodulatory drug therapy
[69]. The currently available commercial assays that are used in measuring cereblon levels have
their own limitations. Therefore, standardization and validation of the techniques used are
needed to accurately assess the role of cerebron as a predictive biomarker of the response to
immunomodulatory drugs [69].
The serine-thionine kinase, casein kinase 1α (CK1α), is encoded by casein kinase 1 A1
(CSNK1A1) gene [72, 73]. CK1α has been implicated in the biology of del (5q) MDS and has
been shown to be a therapeutic target in myeloid malignancies and is therefore an attractive
candidate for mediating the effects of lenalidomide in del (5q) MDS [73]. CSNK1A1 gene is a
putative tumor suppressor gene located in the CDR at 5q 32 for del (5q) MDS and is expressed
at haploinsufficiency levels in MDS with del(5q) [72–74]. Haploinsufficiency of CSNK1A1
leads to hematopoietic stem-cell expansion in mice and may play a role in the initial clonal
expansion in patients with 5q-syndrome [43]. CSNK1A1 gene plays a central role in the biology
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or pathogenesis of del (5q) MDS and is a promising therapeutic target [74]. Lenalidomide
induces the ubiquitination of CSNK1A1 by the E3 ubiquitin ligase [CRL4 CRBN] resulting in
CSNK1A1 degradation. Lenalidomide significantly alters the protein abundance of three out
of five differentiated ubiquitinated proteins [73].
The development of CK1α inhibitors may provide a new therapeutic opportunity in MDS
patients with del (5q) and CSNK1A1 mutations [72]. In MDS patients with del (5q), CSNK1A1
mutations have been found in 7.2% of patients and are associated with older age [72].
CSNK1A1 mutations may coexist with ASKL1 but not with p53 mutations. They are usually
responsive to lenalidomide and have no independent prognostic impact on overall survival
[72].
In del (5q) MDS, lenalidomide-induced degradation of CSNK1A1 below the haploinsufficiency
levels induces p53 activity, that is, CSNK1A1 is a negative regulator of p53 [73]. The deletion
of genes on chromosome 5q, such as RPS-14, may further sensitize del (5q) cells to p53
activation. This mechanism of activity is consistent with the acquisition of TP53 mutations in
del (5q) MDS patients who develop resistance to lenalidomide [73].
Lenalidomide is a potent therapy for low-risk MDS with del (5q) that causes transfusion
independency in 67% of patients and complete cytogenetic remission in 45% of patients [44].
However, 50% of patients responding to lenalidomide relapse within 2 years, and 15% of
patients achieving cytogenetic response, and 67% of patients not achieving cytogenetic
response are at risk of leukemic transformation within 10 years [44].
8.3. The role of HSCT in MDSs
Allogeneic HSCT is the only known curative therapeutic option for MDS [2, 3, 75–84]. Not only
the rates of allogeneic HSCT to treat MDS are continuously increasing, but also survival rates
are steadily improving [76, 85]. In patients with MDS, the indications of HSCT are as follows:
(1) higher-risk MDS, (2) intermediate-2 MDS, (3) MDS in blast cell crisis, (4) younger patients
with MDS having good performance status, and (5) patients with low-risk MDS with poor
prognostic features such as: old age, refractory cytopenias and transfusion-dependence [3, 75,
76, 81, 82]. Both blast percentage and percentage of cytogenetically abnormal cells reflect MDS
disease burden and predict the outcome of HSCT [86]. Therefore, accurate assessment of MDS
disease burden and MDS disease biology based on cytogenetic and molecular profiles is critical
to determine the optimal HSCT timing and improve the outcome of HSCT [86]. Incorporation
of novel diagnostic techniques such as flow cytometry, molecular cytogenetics and microarray
gene expression profiling in the diagnostic algorithms and risk stratification may further
optimize therapeutic decisions including the timing of allogeneic HSCT [85].
In patients with MDS undergoing HSCT, predictors of the outcome of HSCT include the
following: (1) age, (2) performance status, (3) transfusion dependence, (4) serum erythropoietin
level, (5) HSCT-comorbidity index, (6) MK, (7) MDS risk score such as R-IPSS category, and
(8) severity of cytopenias [75, 76, 79, 82]. Novel classification schemes for MDS allow for more
accurate prognostication and consequently recommendations for HSCT or non-HSCT
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therapies [78]. MDS disease classification by IPSS, R-IPSS, and WPSS as well as patient
characteristics as assessed by HSCT-comorbidity index provide guidance for optimal patient
management [81].
Table 12. Clinical trials on lenalidomide in MDS.
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The age of MDS patients undergoing HSCT has increased significantly over the last 30 years.
While HSCT is being carried out in older patients with MDS, this enthusiasm has been over
shadowed by the impact of the procedure and its complications, namely graft versus host
disease (GVHD) on the QOL and socioeconomic status [78]. Comorbid medical conditions are
the major patient characteristics impacting transplantation success. Validation of comorbidity
scoring systems has provided the basis for risk assignment to a given patient [78]. HSCT
comorbidity index allows estimation of the probability of non-relapse mortality after HSCT
[81].
Pre-HSCT serum ferritin > 100 mg/L has been shown to have an adverse impact on OS
following HSCT [75]. Adverse consequences of iron overload on the outcome of HSCT include
increased risk of septicemia, invasive fungal infections, and sinusoidal obstruction syndrome
[75]. BM blast percentage < 5% at the time of HSCT is the major predictor of improved disease-
free survival (DFS) and disease relapse [80]. Prior treatment to decrease blast percentage < 5%
prior to allogeneic HSCT is recommended as it has been shown to improve DFS particularly
in patients undergoing nonmyeloablative (NMA)-conditioning therapy [80].
The major factors that have a negative effect on relapse-free survival in MDS patients subjected
to HSCT are pretransplant karyotype and pre-HSCT BM blast count [76, 81]. Patients with very
poor cytogenetics, including MK, have a 10% or less probability of long-term survival [81].
Studies have also shown that a patient with MDS having MK has lower survival rates, higher
relapse rates, and higher overall mortality following allogeneic HSCT [76]. The presence of
p53, DNMT3A, and TET2 genetic mutations in the pre-HSCT period decreases the probability
of post-transplant survival by a factor of 3–4 [76, 81]. On the other hand, SF3B1 mutations are
associated with superior leukemia-free survival and OS in MDS patients subjected to alloge‐
neic HSCT [81].
In MDS patients receiving allogeneic HSCT, the stem cell sources are the following: peripheral
blood, BM, and umbilical cord blood (UCB) have yielded similar outcomes [80, 83]. Peripheral
blood progenitor cells are currently the preferred source of stem cells due to faster engraftment
and higher risk of GVHD giving rise to more potent graft versus tumor (GVT) effect [81, 83].
Cord blood cells are typically associated with slow engraftment and hence higher risk of
infections and bleeding complications [81]. UCB-derived hematopoietic grafts provide the
advantage of transplanting rather immature cells that allows successful HSCT in some patients
even in the presence of HLA mismatches [87]. The following forms of allografts are available
for MDS patients who are eligible for transplantation: HLA-matched sibling grafts, matched
unrelated donor (MUD) allografts, UCB grafts, and HLA-haploidentical donor allografts [78,
83]. The availability of: HLA matched related and unrelated donors, HLA-haploidentical
relatives and UCB helps to identify donors for the vast majority of MDS patients [81]. Tradi‐
tionally, transplantation of HLA-haploidentical cells carries an increased risk of graft rejection
and an increased risk of GVHD. However, the recently introduced conditioning regimens have
reduced the risk of graft rejection and the administration of cyclophosphamide in the early
post-transplant period has minimized the risk of GVHD to similar or even lower rates than
observed following HLA-matched donor cell [81].
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An increased use of unrelated donors and the establishment of protocols for cord blood HSCT
and HLA-haploidentical HSCT have made HSCT available for a rapidly growing number of
patients [78]. Haploidentical HSCT performed using T-cell replete allografts and post-
transplant cyclophosphamide can achieve outcomes equivalent to those of conventional HSCT
using HLA-matched related or unrelated donors [87]. The preferred donor for MDS patients
undergoing allogeneic HSCT is an HLA-matched sibling or alternatively a fully matched
unrelated donor as both have comparable survival rates. However, MUD form of HSCT is
associated with higher treatment-related mortality (TRM) [82].
Development of a broad range of conditioning regimens has allowed clinicians to offer HSCT
taking into consideration: stage of the disease and patient characteristics [78]. Conventional
myeloablative conditioning (MAC) protocols include the following: total body irradiation
(TBI), cyclophosphamide, busulfan, and fludarabine, while reduced intensity conditioning
(RIC) regimens incorporate low-dose TBI, fludarabine, cyclophosphamide, ATG, and alem‐
tuzumab in various doses and schedules [75]. MAC therapy is associated with lower relapse
rate particularly in patients in complete remission or with < 5% blasts. MAC therapy is also
associated with increased toxicity and nonrelapse mortality [78, 80]. Long-term survival results
in remission following allogeneic HSCT from HLA-matched related or unrelated donor and
high-intensity conditioning treatment are as follows: lower-risk MDS: 75%, intermediate-1
MDS: 60%, intermediate-2 MDS: 45% and high-risk MDS: 30% [81]. NMA or RIC conditioning
regimens may be considered for MDS patients who are not candidates for MAC regimens due
to comorbidities or old age, but such regimens should ideally be used within the context of a
clinical trial [82]. Since approximately 75% of MDS patients are > 60 years of age at diagnosis,
MAC-allogeneic HSCT can only be offered to a subset of individuals [82]. In patients unfit for
MAC therapy, NMA conditioning yields equivalent: TRM, DFS, and OS [80]. For patients with
de novo MDS aged 60–70 years, the favored therapy varies according to the IPSS risk for patients
with low risk and intermediate-1 IPSS risk, nontransplantation approaches are preferred and
for patients with intermediate-2 and high-IPSS risk, RIC-allogeneic HSCT offers overall and
quality-adjusted survival benefit [88]. In patients with MDS, emphasis should be shifted from
high-dose chemotherapy aimed at maximum tumor-cell kill to RIC allogeneic HSCT relying
on the donor cell-mediated GVT effect that is most prominent in patients having chronic
GVHD in particular in order to eradicate the disease [81]. RIC regimens for allogeneic HSCT
have the capacity to result in long-term remissions in MDS patients who are ineligible for
conventional allogeneic HSCT [89]. The role of RIC-allogeneic HSCT in MDS patients is to
induce chronic GVHD which in turn reduces relapse rate and improves DFS and OS [82, 89].
Autologous HSCT is applicable only to a minority of younger patients with MDS because of
difficulty in harvesting adequate numbers of CD34+ cells even in low-risk MDS patients and
lack of graft versus leukemia or GVT effect thus resulting in high risk of MDS relapse [3].
8.4. HSCT in lower risk MDS patients
In patients with low- or intermediate-1-risk MDS, aged 60–79 years, life expectancy following
RIC-allogeneic HSCT is about 38 months compared to 77 months in patients not subjected to
HSCT, that is, there is no survival benefit of HSCT in this category of patients [81]. Patients
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with low or very low-risk MDS should ideally be treated with supportive measures and low
intensity therapies, such as lenalidomide, erythropoiesis stimulating agents, hypomethylating
agents or immunosuppressive therapies rather than allogeneic HSCT [81, 84].
8.5. Road blocks and other unresolved issues related to HSCT in MDSs
The major road blocks to a universally successful HSCT are relapse of MDS and NRM, often
related to GVHD [75, 78, 83]. Allogeneic HSCT in MDS patients can lead to considerable
mortality and morbidity mostly as a consequence of toxicity to organs, infectious complications
and GVHD [87]. Acute and chronic GVHD are frequent causes of morbidity after HSCT in
MDS patients [78]. Additional research is required to prevent GVHD while maintaining the
GVT effect [81]. The graft versus dysplasia resulting from allogeneic HSCT and the infusion
of donor leukocytes has led to a great understanding of the immunological mechanisms that
govern the outcome of HSCT in MDS patients [3]. Post-transplant relapse is a major hurdle to
greater success, particularly in patients with high-risk cytogenetics [78]. Pretransplant
cytogenetics and BM blasts are the strongest risk factors for post-HSCT relapse [81]. The time
interval from allogeneic HSCT until relapse represents a crucial factor to predict response to
salvage therapy and survival in patients with high-risk MDS relapsing after allogeneic HSCT
[90]. Strategies to reduce relapse and TRM and improve outcome of HSCT include the
following: (1) modification of the intensity of conditioning therapy taking into consideration:
age, organ function and comorbid medical conditions, (2) pretransplantation strategies that
include (A) improvement of remission: (a) hypomethylating agents and/or histone deacetylase
inhibitors (HDACs), (b) induction therapy followed by RIC (FLAMSA), and (c) clofarabine
and/or cytosine arabinoside. (B) induction of cytogenetic remission by lenalidomide for 5q-
syndrome and hypomethylating agents for monosomy 7, and (3) post-transplantation strat‐
egies that include (a) boosting GVL effect by immune enhancers such as lenalidomide, CTLA4
(cytotoxic T-lymphocyte-associated protein 4), anti-PDL1 (programmed death-ligand 1) and
adoptive transfer of tumor-reactive T cells and natural killer cells, (b) maintenance with
HDACs and/or donor lymphocyte infusion (DLI), and (c) maintenance with lenalidomide and/
or DLI [83, 91].
The following represent the unresolved issues related to HSCT in MDS: (1) timing of the
transplant; standard conditioning for younger patients and RIC for older patient with comor‐
bidities, (2) disease status at transplant, (3) pre-HSCT therapy or pretransplant tumor debulk‐
ing with traditional chemotherapeutic agents or the novel DNA hypomethylating drugs, (4)
the intensity of the conditioning therapies, (5) stem cell source and alternative donors, (6)
optimal therapy for intermediate-risk MDS, and (7) the combination of HSCT with novel
therapies such as hypomethylating agents and immunomodulatory drugs [3, 79, 80, 84, 92].
As MDS patients are usually on the old side, QOL is a top priority for most patients, so
discussion regarding transplantation in older patients must include not only the acute effects
of transplantation but also the delayed effects [81]. Incorporation or integration of novel non-
HSCT therapeutic modalities in the overall management of MDS patients undergoing
allogeneic HSCT is needed [78].
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9. Prognosis in low-risk MDS
There are several poor prognostic factors in patients with MDS. The poor prognostic factors
in MDS in general are listed in Table 13 [47]. However, in low-risk disease, the following factors
have been found to correlate with poor prognosis: (1) severe anemia, (2) transfusion depend‐
ence, (3) poor performance status, (4) older age, (5) number and severity of medical comor‐
bidities, (6) leukocytosis, and (7) elevated level of serum LDH [4].
1. Old age
2. Poor performance status
3. Presence of comorbid medical conditions
4. WBC count > 20 × 109/L
5. Severe anemia
6. Severe or refractory thrombocytopenia; PLTs <30 × 109/L
7. Eosinophilia: > 350/microliter (μL) and basophilia: > 250/μL
8. Absolute lymphocytic count < 1200/mL
9. Reduced platelet mass
10. Transfusion dependence
11. Presence of bone marrow fibrosis
12. CD34 positivity of nucleated BM cells
13. RBC-MCV (mean corpuscular volume) < 100 FL
14. Increased expression of WT1 (Wilm's tumor gene)
15. Monsomy 5 or del (5q) associated with other chromosomal abnormalities
16. Specific genetic mutations: TP53/TET2/DNMT3A/FLT3/EZH2/ETV6/BCOR
17. Reduced circulating endothelial cells
18. Increased levels of: TNF-α, single-nucleotide polymorphism in TNF gene
19. Increased serum B2 microglobulin concentration
20. Downregulation of granulopoiesis regulator lymphoid enhancer-binding factor 1 (LEF1)
21. Abnormal localization of immature precursors (ALIP)
22. Increased DNA methylation
23. Failure of decitabine therapy
Table 13. Adverse prognostic factors in MDS.
In patients with del (5q), the following factors have been found to be independent predictors
of shortened survival: age, transfusion need at diagnosis and dysgranulopoiesis [18, 19].
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10. Conclusions and future perspectives
MDSs including 5q-syndrome are often complicated by BM suppression reflected by cytope‐
nias, infectious complications, iron overload and transformation into AML. Management of
these disorders includes the following: (1) supportive care that comprises transfusion of blood
products, antimicrobials, growth factors, and iron chelation therapy; (2) targeted therapies,
such as lenalidomide, and (3) various forms of HSCT. The role of allogeneic HSCT in MDSs is
surging as the recently introduced conditioning therapies have allowed application of this
curative therapy to older patients and those with comorbid medical conditions. The recent
developments in the science of MDSs will allow more advanced targeted therapies to be
integrated into the therapeutic algorithms of these disorders.
The role of cereblon as a molecular target for lenalidomide and pomalidomide and that of
CK1α in mediating the effects of lenalidomide will ultimately translate into more refined
targeted therapies for patients with del (5q) MDS. Also, early incorporation of more pinpointed
targeting of clones harboring TP53 mutations and utilization of the translation enhancer, L-
leucine, will further improve not only the management but also the outcome of patients with
5q-syndrome.
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